Boston Scientific Corporation $BSX Shares Newly Acquired by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Boston Scientific Corporation (NYSE:BSX) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor purchased 400,074 shares of the medical equipment provider’s stock, valued at approximately $17,463,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vise Technologies Inc. raised its holdings in shares of Boston Scientific by 22.6% in the third quarter. Vise Technologies Inc. now owns 35,744 shares of the medical equipment provider’s stock worth $1,560,000 after buying an additional 6,585 shares during the period. Cidel Asset Management Inc. purchased a new position in Boston Scientific during the 3rd quarter valued at $212,000. MGO One Seven LLC boosted its holdings in Boston Scientific by 1.9% during the 3rd quarter. MGO One Seven LLC now owns 14,061 shares of the medical equipment provider’s stock valued at $614,000 after acquiring an additional 260 shares during the period. Americana Partners LLC purchased a new position in Boston Scientific during the 3rd quarter valued at $740,000. Finally, State of Wyoming grew its position in Boston Scientific by 447.8% in the 3rd quarter. State of Wyoming now owns 5,336 shares of the medical equipment provider’s stock valued at $233,000 after acquiring an additional 4,362 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Stock Performance

Shares of Boston Scientific stock opened at $43.58 on Wednesday. The company has a market capitalization of $63.15 billion, a PE ratio of 18.47, a P/E/G ratio of 1.29 and a beta of 0.60. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. The company has a 50-day simple moving average of $44.55 and a two-hundred day simple moving average of $56.38. Boston Scientific Corporation has a one year low of $39.57 and a one year high of $105.65.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, meeting the consensus estimate of $0.73. Boston Scientific had a net margin of 16.62% and a return on equity of 18.73%. The business had revenue of $5.14 billion during the quarter, compared to analyst estimates of $5.09 billion. During the same period in the prior year, the firm posted $0.75 earnings per share. The company’s quarterly revenue was up 1.4% on a year-over-year basis. Research analysts expect that Boston Scientific Corporation will post 3.17 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on BSX shares. Stifel Nicolaus reduced their target price on Boston Scientific from $60.00 to $55.00 and set a “buy” rating on the stock in a research note on Monday, October 26th. JPMorgan Chase & Co. lowered shares of Boston Scientific from an “overweight” rating to a “neutral” rating and set a $46.00 target price for the company. in a research note on Wednesday, October 28th. Jefferies Financial Group cut shares of Boston Scientific from a “buy” rating to a “hold” rating and cut their price target for the stock from $60.00 to $46.00 in a report on Wednesday, October 28th. Canaccord Genuity Group reduced their price target on shares of Boston Scientific from $66.00 to $48.00 and set a “buy” rating on the stock in a research note on Thursday, October 29th. Finally, UBS Group decreased their price objective on shares of Boston Scientific from $67.00 to $57.00 and set a “buy” rating for the company in a report on Thursday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $61.43.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported that the SIMPLAAFY trial of its WATCHMAN FLX Pro heart device met its six-month primary endpoints. The results found two post-implant drug regimens non-inferior to dual-antiplatelet therapy, potentially supporting simpler treatment after the procedure. Article: SIMPLAAFY study results
• Neutral Sentiment: Boston Scientific and Blackstone Life Sciences announced a $455 million collaboration to co-develop the VITALYST heart-pump technology. The arrangement may ease near-term development costs, but an analyst noted it could defer growth and leave longer-term uncertainty. Article: VITALYST collaboration Article: Analyst assessment of VITALYST deal
• Negative Sentiment: A Zacks analysis flagged weakening earnings estimates, softer momentum in core businesses and major growth catalysts that may not arrive until 2028. Those concerns could overshadow the company’s valuation discount. Article: Valuation and earnings-growth analysis
• Negative Sentiment: J.P. Morgan maintained a Hold rating, while TD Cowen also cut its rating to Hold; Barclays lowered its price target. The cautious analyst stance adds to concerns about near-term growth. Article: J.P. Morgan rating Article: TD Cowen rating Article: Barclays price-target change

Boston Scientific Company Profile

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.